A Dose-Ranging Study of Cabozantinib in Men with Castration-Resistant Prostate Cancer and Bone MetastasesRichard J. Lee, Matthew R. Smith, Philip J. Saylor et al.|Clinical Cancer Research|2013Cited by 74
Investigator-sponsored trial of efficacy and tolerability of cabozantinib (cabo) at lower dose: A dose-finding study in men with castration-resistant prostate cancer (CRPC) and bone metastases.Richard J. Lee, Matthew R. Smith, M. Dror Michaelson et al.|Journal of Clinical Oncology|2012Cited by 2
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Thai H. Ho et al.|Unknown|2023Cited by 0
Table S1 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Toni K. Choueiri et al.|Unknown|2023Cited by 0
Table S3 from Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell CarcinomaDavid J. Kwiatkowski, Sabina Signoretti, Toni K. Choueiri et al.|Unknown|2023Cited by 0